Clinical Trials · NCT00081159
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 80
- Start date
- Jul 2004
- Locations
- 4 sites, United States
- Primary endpoint
- Progression Free Survival (PFS)